<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37350306</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes.</ArticleTitle><Pagination><StartPage>1467</StartPage><EndPage>1480</EndPage><MedlinePgn>1467-1480</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51836</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease involving both upper and lower motor neurons. The motor phenotypes of ALS are highly clinically heterogeneous, and the underlying mechanisms are poorly understood.</AbstractText><AbstractText Label="METHODS">A comparative proteomic analysis was performed in the cerebrospinal fluid (CSF) of bulbar-onset (BO) and spinal-onset (SO) ALS patients and controls (n&#x2009;=&#x2009;14). Five biomarker candidates were selected from a differentially regulated protein pool, and further validation was performed in a larger independent cohort (n&#x2009;=&#x2009;92) using enzyme-linked immunosorbent assay (ELISA).</AbstractText><AbstractText Label="RESULTS">A total of 1732 CSF proteins were identified, and 78 differentially expressed proteins were found among BO-ALS patients, SO-ALS patients, and controls. Five promising biomarker candidates were selected for further validation, and lipopolysaccharide-binding protein (LBP) and HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) were validated. CSF LBP levels were increased in ALS patients compared with controls and higher in BO-ALS versus SO-ALS. The increased CSF LBP levels were correlated with the revised ALS Functional Scale (ALSFRS-R) score. CSF HLA-DRA levels were specifically elevated in BO-ALS patients, and there was no significant difference between SO-ALS patients and controls. Increased HLA-DRA expression was correlated with decreased survival.</AbstractText><AbstractText Label="INTERPRETATION">Our data shows that elevated CSF LBP is a good biomarker for ALS and correlates with clinical severity, and increased HLA-DRA is a specific biomarker for BO-ALS and may predict short survival. It also suggests that the microglial pathway and HLA-II-related adaptive immunity may be differentially involved in ALS phenotypes and may be new therapeutic targets for ALS.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Jinxia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zeng</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Qiao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, 210029, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Wenping</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Dandan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, 928 Hospital of Joint Logistics Support Force of PLA, Haikou, 571100, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Sizhuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5724-3535</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059805">HLA-DR alpha-Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059805" MajorTopicYN="N">HLA-DR alpha-Chains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37350306</ArticleId><ArticleId IdType="pmc">PMC10424661</ArticleId><ArticleId IdType="doi">10.1002/acn3.51836</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ludolph AC, Schuster J, Dorst J, et&#xa0;al. Safety and efficacy of rasagiline as an add&#x2010;on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled, phase 2 trial. Lancet Neurol. 2018;17(8):681&#x2010;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661&#x2010;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS Study Group . Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740&#x2010;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry. 2007;78(6):629&#x2010;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077959</ArticleId><ArticleId IdType="pubmed">17088331</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009;256(4):615&#x2010;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">19296046</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, et&#xa0;al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;89(4):367&#x2010;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et&#xa0;al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59&#x2010;e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Goossens J, et&#xa0;al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2019;45(3):291&#x2010;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Silani V, Otto M. Neurochemical biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32(5):747&#x2010;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">31403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Otto M, Silani V. Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2021;15:679199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8255624</ArticleId><ArticleId IdType="pubmed">34234641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Lee BH, Yip W, Chou P, Yip BS. Neurofilament proteins as prognostic biomarkers in neurological disorders. Curr Pharm des. 2020;25(43):4560&#x2010;4569.</Citation><ArticleIdList><ArticleId IdType="pubmed">31820696</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP&#x2010;43&#x2010;based biomarker for ALS and FTLD. Mol Neurobiol. 2018;55(10):7789&#x2010;7801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Oeckl P, Feneberg E, et&#xa0;al. Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. Expert Rev Proteomics. 2021;18(11):977&#x2010;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">34758687</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Thal DR, Weishaupt JH, Ludolph AC, Otto M. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020;139(1):119&#x2010;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">31701227</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P, Oeckl P, Steinacker P, et&#xa0;al. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. J Neurol Neurosurg Psychiatry. 2020;91(5):503&#x2010;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">32132225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et&#xa0;al. A revision of the El Escorial criteria&#x2014;2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):291&#x2010;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, et&#xa0;al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;90(12):1338&#x2010;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Su D, Zhang Y, Bi F, Xiao B. [proteomic analysis of the cerebrospinal fluid from patients with amyotrophic lateral sclerosis based on tandem mass spectrometry technique]. Nan Fang Yi Ke Da Xue Xue bao =. Journal of Southern Medical University. 2019;39(4):428&#x2010;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6743996</ArticleId><ArticleId IdType="pubmed">31068286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Wuolikainen A, Wu J, et&#xa0;al. Targeted multiple reaction monitoring analysis of CSF identifies UCHL1 and GPNMB as candidate biomarkers for ALS. J Mol Neurosci. 2019;69(4):643&#x2010;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858390</ArticleId><ArticleId IdType="pubmed">31721001</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E, Bremang M, Mitra V, et&#xa0;al. Combined tissue&#x2010;fluid proteomics to unravel phenotypic variability in amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):4478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6418138</ArticleId><ArticleId IdType="pubmed">30872628</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et&#xa0;al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084&#x2010;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, Song Z, Liu A, Dahmen U, Yang X, Fang H. Effects of lipopolysaccharide&#x2010;binding protein (LBP) single nucleotide polymorphism (SNP) in infections, inflammatory diseases. Metabolic Disorders and Cancers Front Immunol. 2021;12:681810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8290185</ArticleId><ArticleId IdType="pubmed">34295331</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, et&#xa0;al. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):15295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HS, Son J, Lee D, et&#xa0;al. Gut&#x2010; and oral&#x2010;dysbiosis differentially impact spinal&#x2010; and bulbar&#x2010;onset ALS, predicting ALS severity and potentially determining the location of disease onset. BMC Neurol. 2022;22(1):62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862222</ArticleId><ArticleId IdType="pubmed">35189854</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasi A, Intini A, Divella C, et&#xa0;al. Emerging role of lipopolysaccharide binding protein in sepsis&#x2010;induced acute kidney injury. Nephrol Dial Transplant. 2017;32(1):24&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">27387474</ArticleId></ArticleIdList></Reference><Reference><Citation>Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med. 2013;45:e66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880462</ArticleId><ArticleId IdType="pubmed">24310172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaltman C, Braulio VB, Outeiral R, Nunes T, de Castro CL. Lower extremity mobility limitation and impaired muscle function in women with ulcerative colitis. J Crohns Colitis. 2014;8(6):529&#x2010;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">24315794</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes RB, Ahn J, Fan X, et&#xa0;al. Association of oral microbiome with Risk for incident head and neck squamous cell cancer. JAMA Oncol. 2018;4(3):358&#x2010;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885828</ArticleId><ArticleId IdType="pubmed">29327043</ArticleId></ArticleIdList></Reference><Reference><Citation>Auffray C, Kuo J, DeMars R, Strominger JL. A minimum of four human class II alpha&#x2010;chain genes are encoded in the HLA region of chromosome 6. Nature. 1983;304(5922):174&#x2010;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">6306475</ArticleId></ArticleIdList></Reference><Reference><Citation>Handunnetthi L, Ramagopalan SV, Ebers GC, Knight JC. Regulation of major histocompatibility complex class II gene expression, genetic variation and disease. Genes Immun. 2010;11(2):99&#x2010;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987717</ArticleId><ArticleId IdType="pubmed">19890353</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliseychik MP, Andreeva TV, Rogaev EI. Immunogenetic factors of neurodegenerative diseases: the role of HLA class II. Biochemistry (Mosc). 2018;83(9):1104&#x2010;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">30472949</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Luber&#x2010;Narod J, Styren SD, Civin WH. Expression of immune system&#x2010;associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988;9(4):339&#x2010;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">3263583</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Civin WH, Rogers J. Molecular, cellular, and pathologic characterization of HLA&#x2010;DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol. 1990;110(1):93&#x2010;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">1698655</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse S, Steiner J, Alter J, et&#xa0;al. Expression of HLA&#x2010;DR, CD80, and CD86 in healthy aging and Alzheimer's disease. J Alzheimers Dis. 2015;47(1):177&#x2010;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">26402766</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D, Van den Oord JJ, Vianney de Jong JM. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 1990;16(5):401&#x2010;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">2263315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992;140(3):691&#x2010;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K, Kobatake Y, Asahina R, et&#xa0;al. Up&#x2010;regulated inflammatory signatures of the spinal cord in canine degenerative myelopathy. Res Vet Sci. 2021;135:442&#x2010;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">33187678</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715&#x2010;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>